MYCN and the Epigenome
It is well known that Neuroblastoma (NB) patients whose tumors have an undifferentiated histology and a transcriptome enriched in cell cycle genes have a worse prognosis. This contrasts with the good prognoses of patients whose tumors have histologic evidence of differentiation and a transcriptome e...
Main Authors: | Stanley eHe, Zhihui eLiu, Doo-Yi eOh, Carol J Thiele |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00001/full |
Similar Items
-
Epigenetic Dysregulation in <i>MYCN</i>-Amplified Neuroblastoma
by: Soraya Epp, et al.
Published: (2023-12-01) -
TARGETING THE EPIGENOME IN LUNG CANCER: EXPANDING APPROACHES TO EPIGENETIC THERAPY
by: Marko eJakopovic, et al.
Published: (2013-10-01) -
Targeting MYCN in Pediatric and Adult Cancers
by: Zhihui Liu, et al.
Published: (2021-02-01) -
MYCN in Neuroblastoma: “Old Wine into New Wineskins”
by: Maria Braoudaki, et al.
Published: (2021-10-01) -
MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin.
by: Samuele eGherardi, et al.
Published: (2013-03-01)